leisure time -WSS

leisure time

author：focus 2025-10-02 18:14:19 - browse：25613

NEW ORLEANS — For some patients suffering with certain blood cancers, CAR-T therapy can offer the tantalizing chance to end their disease with a single treatment.

But the immunotherapy takes time to manufacture, and patients often have to wait weeks to actually receive an infusion once they’re eligible. For some patients with especially aggressive cancer, they can die while waiting for the therapy to arrive.

That’s spurred CAR-T manufacturers to find ways to speed up manufacturing. The industry is testing newer — and possibly better — CAR-T cells that can be made more quickly. Researchers working with Novartis presented Phase 1 clinical trial data Sunday on a new CAR-T cell made with a rapid manufacturing process at the annual American Society of Hematology meeting.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Doctors find melanoma drugs effective against rare brain cancer

leisure time

WSS

How Medicaid coverage policies for immigrants impact new moms

Doctors find melanoma drugs effective against rare brain cancer

White House Covid adviser calls on docs to combat misinformation

Midwives could help bridge maternal health disparities in the U.S.

AI can’t replace a physician’s gut feeling

Sanders adds drug shortage policies to pandemic preparedness bill

Wikipedia

leisure time

knowledge

Cancer drug shortages should be causing more outrage

Fed up with FDA, ALS advocates consider a take

How to save PrEP access — and even expand it

A public scorecard can help hold safety

Affirmative action in medical school literally saved lives

Key House panel plots a new health care package

Hepatitis C has a cure — but many Americans still lack access to it

Transgender sports debate: Physicians say bans are health issue

Peter Hotez and the public health issue of online harassment

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

hotspot

How the messy conversation about Dolly changed bioethics

Sanofi seeks simpler, safer CRISPR sickle cell cure

Eli Lilly CEO gives to Mike Pence presidential super PAC

Medicare has a new plan to address drug shortages

FDA panel to weigh safety of artificial wombs for preterm births

Covid’s new normal has set in amid another rise in cases

leisure time

focus

leisure time

focus